广东丸美生物技术股份有限公司

Core Points - The company has ensured the authenticity, accuracy, and completeness of the quarterly report, taking legal responsibility for any misleading statements or omissions [2][7][34] - The company held its fifth board meeting on October 29, 2025, where the third-quarter report was approved unanimously [8][9] - The company received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau regarding financial accounting irregularities and improper use of raised funds [34][35][36] Financial Data - The third-quarter financial statements were not audited [3] - The company reported significant changes in financial data and indicators, which are detailed in the quarterly report [5][9] Shareholder Information - The company disclosed information regarding the total number of shareholders and the situation of the top ten shareholders [5] Meeting Resolutions - The board approved the third-quarter report, the cancellation of the supervisory board, and the correction of prior accounting errors [12][21] - A second extraordinary general meeting for 2025 was also approved [15][16] Regulatory Compliance - The company is committed to rectifying the issues identified by the regulatory authority and enhancing compliance awareness [36][37] - The company will continue to fulfill its information disclosure obligations as per legal requirements [37] Product and Pricing Information - The average selling prices of eye care and beauty products increased due to changes in sales mix and marketing strategies [24][25] - The company reported price fluctuations in key raw materials, with some prices decreasing significantly [27][28][30][32]